Common Side Effects of Polivy
Polivy (polatuzumab vedotin), used with bendamustine and rituximab to treat relapsed or refractory diffuse large B-cell lymphoma, causes side effects mainly from its chemotherapy-like action targeting CD79b on B-cells. Most patients experience fatigue (41%), low white blood cell counts (neutropenia, 40%), diarrhea (31%), and low platelet counts (thrombocytopenia, 28%). Other frequent issues include nausea (26%), anemia (24%), constipation (21%), and peripheral neuropathy (21%), often described as numbness or tingling in hands and feet.[1][2]
Serious Side Effects Patients Report
Severe reactions hit about 40-50% of users. These include life-threatening infections from low neutrophils (febrile neutropenia, 25%), pneumonia (13%), and sepsis. Infusion reactions occur in 39%, with symptoms like fever, chills, or breathing trouble during or shortly after dosing—premedication with antihistamines and steroids reduces this. Progressive multifocal leukoencephalopathy (PML), a rare brain infection from JC virus reactivation, has been fatal in some cases. Liver problems (elevated enzymes) and tumor lysis syndrome also arise, especially early in treatment.[1][3]
How Side Effects Compare to Rituximab-Bendamustine Alone
Adding Polivy worsens blood count drops versus rituximab-bendamustine (RB) alone: neutropenia jumps from 29% to 40%, thrombocytopenia from 26% to 28%, anemia from 21% to 24%. Neuropathy and fatigue increase notably, but response rates improve (40% complete response with Polivy-RB vs. 18% with RB). Most neuropathy stabilizes or improves after stopping, but 5% is permanent.[2][4]
Long-Term Risks and What Happens After Stopping
Peripheral neuropathy persists in 10-15% of patients beyond 6 months, sometimes requiring dose delays or reductions (22% of cases). Fatigue and blood issues often resolve post-treatment, but monitoring for secondary cancers or heart issues continues. PML risk lingers due to B-cell depletion. Patients with liver impairment face higher toxicity; dose adjustments apply for bilirubin levels over 1.5x upper normal.[1][3]
Who Gets Hit Hardest and Management Tips
Older adults (over 65) see higher severe event rates (48% vs. 37% under 65). Those with prior stem cell transplants or poor performance status report more issues. Doctors manage with growth factors for neutropenia, holding doses for neuropathy grade 2+, and supportive care for GI symptoms. Report fever over 100.4°F or new numbness immediately.[2][4]
[1]: Polivy Prescribing Information (Genentech, 2023)
[2]: FDA Label for Polivy
[3]: Drugs.com - Polivy Side Effects
[4]: GO29365 Trial Data (Lancet Oncology, 2019)